The Liver's Last Stand: vTv Therapeutics Reaches Pivotal Phase 3 Milestone

HIGH POINT, N.C. – October 05, 2026 — For decades, the holy grail of Type 1 diabetes management has been an oral adjunctive therapy—a daily pill that could smooth out the treacherous spikes and crashes of blood glucose without replacing insulin. Yet, the pharmaceutical landscape is littered with the remnants of failed attempts to bring such a drug to market. Now, a small-cap biopharmaceutical company in North Carolina is attempting to rewrite that narrative.

vTv Therapeutics (Nasdaq: VTVT) announced today that it has completed patient enrollment for its Phase 3 CATT1 study. The trial is evaluating cadisegliatin, an investigational oral therapy designed to be taken alongside insulin by adults with Type 1 diabetes (T1D). With 166 patients randomized across three treatment arms, the company is officially on the clock for a mid-2027 data readout that could fundamentally alter both the standard of care in endocrinology and the company’s financial trajectory.

“Completing enrollment for the CATT1 study is a significant milestone for vTv, and we’re deeply grateful to the study participants whose commitment made this possible,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027.”

The Graveyard of Adjunctive Therapies

To understand the magnitude of vTv Therapeutics' current clinical endeavor, one must first examine the regulatory graveyard of T1D adjunctive therapies. Today, an estimated 9.5 million people worldwide live with the autoimmune condition, a number projected to surge to 14.7 million by 2040. Despite remarkable advancements in continuous glucose monitoring (CGM) and automated insulin delivery systems, optimal day-to-day glycemic control remains elusive for a vast majority of patients.

Historically, pharmaceutical companies have attempted to repurpose Type 2 diabetes drugs—specifically SGLT inhibitors like sotagliflozin, empagliflozin, and dapagliflozin—for T1D. These drugs work by forcing the kidneys to excrete excess glucose through urine. While effective at lowering HbA1c and increasing time in target glucose ranges, they carry a fatal flaw for T1D patients: a drastically increased risk of diabetic ketoacidosis (DKA).

The U.S. Food and Drug Administration (FDA) has drawn a hard line on this safety signal. The agency has repeatedly rejected SGLT inhibitors for T1D, culminating in a final rejection of Lexicon Pharmaceuticals’ sotagliflozin in late 2024, prompting the company to abandon the indication entirely. The regulatory consensus is clear: any non-insulin add-on therapy must prove it can improve glycemic control without triggering euglycemic DKA—a dangerous condition where blood becomes acidic even when blood sugar levels appear relatively normal.

Currently, the only oral non-insulin adjunctive therapy approved for T1D in the U.S. is pramlintide, an injectable medication with modest efficacy and significant gastrointestinal side effects that limit its clinical utility. This massive unmet need is the precise gap cadisegliatin is engineered to fill.

A Hepatic Approach to Glycemic Control

Unlike the kidney-targeting SGLT inhibitors, cadisegliatin takes a fundamentally different biological route. The drug is a novel, oral, small-molecule glucokinase activator that acts selectively on the liver.

In a healthy human, insulin released from the pancreas travels directly to the liver via the portal vein, stimulating glucokinase—an enzyme that acts as a sensor to pull glucose out of the bloodstream and store it as glycogen. In individuals with T1D, injected insulin enters the peripheral bloodstream rather than the portal vein. As a result, the liver is constantly starved of the insulin signaling required to activate glucokinase, leaving it unable to properly regulate blood sugar.

Cadisegliatin bypasses this broken signaling pathway. It binds directly to glucokinase in the liver, enhancing its activity independently of insulin. By trapping glucose inside liver cells and promoting its storage, the drug mimics the effect of a healthy pancreas on the liver. Crucially, because it is liver-selective, it does not stimulate the pancreas to release insulin (which could cause dangerous lows) and, based on Phase 2 data, it does not promote the production of ketones.

In the Phase 2 SimpliciT1 study, cadisegliatin demonstrated a statistically significant reduction in HbA1c while simultaneously driving a roughly 40% reduction in severe or symptomatic hypoglycemia compared to a placebo. Furthermore, during acute insulin withdrawal tests, patients on cadisegliatin actually showed a decreased incidence of DKA compared to those on placebo.

This rare combination of improved efficacy and a clean safety profile earned cadisegliatin a Breakthrough Therapy designation from the FDA, signaling the agency's recognition of its potential to clear the high safety bar that doomed its predecessors.

“This milestone is an important step forward for the cadisegliatin program,” noted Thomas Strack, MD, Chief Medical Officer of vTv Therapeutics. “Our focus now is maintaining the quality and integrity of the study through completion and continuing the important work of advancing cadisegliatin development toward potential approval.”

The Financial Tightrope to 2027

While the science is promising, the business of biotechnology is an exercise in financial endurance. vTv Therapeutics is navigating the classic small-cap biotech tightrope: funding a massive, capital-intensive Phase 3 trial while generating zero commercial product revenue.

As of the end of the second quarter of 2026, the company reported cash and cash equivalents of $86.6 million. This reserve is the lifeblood of the organization, carefully calibrated to sustain operations through the highly anticipated mid-2027 topline data readout.

The company's burn rate reflects the heavy lifting of late-stage clinical development. In Q2 2026, research and development expenses hit $8.8 million, contributing to a net loss of $13.1 million for the quarter. However, vTv has been strategic in extending its runway. An $80 million private placement in September 2025 fortified its balance sheet, and a lucrative licensing deal with Newsoara Biopharma in early 2026 injected an additional $36.8 million in upfront fees into the company's coffers.

With a market capitalization hovering around $120 million, vTv Therapeutics remains a high-risk, high-reward proposition for investors. The CATT1 study is a binary event. The trial is evaluating patients over a 52-week period—with primary efficacy and safety assessed at the six-month mark—measuring the incidence of level 2 (clinically significant) and level 3 (severe) hypoglycemic events.

If the data confirms the Phase 2 findings, cadisegliatin will be positioned as a first-in-class blockbuster therapy in a market desperate for innovation. "For a company of this size, holding a Breakthrough Therapy designation in a Phase 3 trial for a globally prevalent disease is incredibly rare," noted one biotech equity analyst who covers the diabetes sector. "The mid-2027 readout isn't just about moving a stock price; it's about validating an entirely new mechanism of action that could redefine adjunctive care."

As the last enrolled patient begins their dosing regimen, the broader healthcare sector will be watching closely. The failure of past therapies has created a skeptical market, but by targeting the liver rather than the kidneys, vTv Therapeutics has engineered a scientifically elegant workaround to a decades-old problem. Whether that elegance translates into definitive Phase 3 clinical success is a question that will take until the summer of 2027 to answer.